A double blind, placebo-controlled phase II study revealed that the antihistamine,
Dimebon®(dimebolin, latrepirdine) improved cognition in Alzheimer disease (AD) patients …

Background Dimebon is a retired non-selective antihistamine drug currently being
investigated as a therapeutic agent for the treatment of Alzheimer's disease (AD). Results …

Dimebon has been tested as a potential modifier of Alzheimer's disease (AD), resulting in
mixed clinical trial outcomes. Originally utilized as an antihistamine, Dimebon was later …

A non-selective antihistamine, dimebon, has recently emerged as a potential treatment for
Alzheimer's disease and Huntington's disease. Dimebon exerts several effects in addition to …

Alzheimer's disease (AD) is the most common type of dementia characterized by abnormal
accumulation of amyloid-β (Aβ) plaques, neuroinflammation, and neuronal loss. Dimethyl …

Dimebon (dimebolin) treatment enhances cognition in patients with Alzheimer's disease
(AD) or Huntington's disease. Although Dimebon was originally thought to improve cognition …

Inhibition of phosphodiesterase 2 and 4 (PDE2A and PDE4) increases the intracellular
cAMP and/or cGMP levels, which may prevent Amyloid β 42 oligomers (Aβ) related cognitive …

Background Recent reports suggest that latrepirdine (Dimebon™, dimebolin), a retired
Russian antihistamine, improves cognitive function in aged rodents and in patients with mild …

Background Dimebon is an antihistamine compound with a long history of clinical use in
Russia. Recently, Dimebon has been proposed to be useful for treating neurodegenerative …

Memantine, a noncompetitive NMDA receptor antagonist with neuroprotective properties,
has been used for the treatment of Alzheimer's disease (AD). Administration of memantine to …